Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · Real-Time Price · USD
6.51
-0.06 (-0.91%)
Mar 20, 2026, 4:00 PM EDT - Market closed
Cartesian Therapeutics Stock Forecast
RNAC's stock price has decreased by -57.89% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 6 analysts that cover Cartesian Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $35, which forecasts a 437.63% increase in the stock price over the next year. The lowest target is $16 and the highest is $44.
Price Target: $35 (+437.63%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Cartesian Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Reiterates $38 | Buy | Reiterates | $38 | +483.72% | Mar 10, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Hold → Buy Upgrades $16 | Hold → Buy | Upgrades | $16 | +145.78% | Mar 9, 2026 |
| Needham | Needham | Strong Buy Reiterates $42 | Strong Buy | Reiterates | $42 | +545.16% | Mar 9, 2026 |
| Needham | Needham | Strong Buy Maintains $40 → $42 | Strong Buy | Maintains | $40 → $42 | +545.16% | Jan 9, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $40 → $30 | Strong Buy | Maintains | $40 → $30 | +360.83% | Nov 19, 2025 |
Financial Forecast
Revenue This Year
407.49K
from 2.80M
Decreased by -85.43%
Revenue Next Year
407.49K
from 407.49K
EPS This Year
-3.44
from -5.02
EPS Next Year
-3.83
from -3.44
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 2.5M | 2.5M | |||
| Avg | 407,490 | 407,490 | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -10.0% | 517.7% | |||
| Avg | -85.4% | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -2.75 | -2.85 | |||
| Avg | -3.44 | -3.83 | |||
| Low | -3.72 | -4.72 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.